The PLATO trial reveals further opportunities to improve outcomes in patients with acute coronary syndrome

Lars Wallentin; Richard C. Becker; Stefan K. James; Robert A. Harrington

doi:10.1160/TH11-03-0162

Thrombosis and Haemostasis, Inhaltsverzeichnis

Thromb Haemost 2011; 105(05): 760-762
DOI: 10.1160/TH11-03-0162

Current Controversies

Schattauer GmbH

The PLATO trial reveals further opportunities to improve outcomes in patients with acute coronary syndrome

Authors

Lars Wallentin

¹Uppsala Clinical Research Centre, Uppsala, Sweden
Richard C. Becker

²Duke Clinical Research Institute, Durham, North Carolina, USA
Stefan K. James

¹Uppsala Clinical Research Centre, Uppsala, Sweden
Robert A. Harrington

²Duke Clinical Research Institute, Durham, North Carolina, USA

Abstract

Volltext

Referenzen

References
1 Anderson JL. et al. ACC/AHA 2007 guidelines for the management of patients with unstable angina/ non ST-elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines for the Management of Patients With Unstable Angina/Non ST-Elevation Myocardial Infarction): developed in collaboration with the American College of Emergency Physicians, the Society for Cardiovascular Angiography and Interventions, and the Society of Thoracic Surgeons: endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation and the Society for Academic Emergency Medicine. Circulation 2007; 116: e148-304.
2 Antman EM. et al. 2007 focused update of the ACC/ AHA 2004 guidelines for the management of patients with ST-elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 2008; 51: 210-247.
3 Bassand JP, Hamm C. New European guidelines for the management of patients with unstable angina/ non-ST-elevation myocardial infarction--what are the new and key messages. Polskie Arch Med Wewnetrznej 2007; 117: 391-393.
4 Van de Werf F. et al. Management of acute myocardial infarction in patients presenting with persistent ST-segment elevation: the Task Force on the Management of ST-Segment Elevation Acute Myocardial Infarction of the European Society of Cardiology. Eur Heart J 2008; 29: 2909-2945.
5 Prasad A. et al. Prognostic significance of periprocedural versus spontaneously occurring myocardial infarction after percutaneous coronary intervention in patients with acute coronary syndromes: an analysis from the ACUITY (Acute Catheterization and Urgent Intervention Triage Strategy) trial. J Am Coll Cardiol 2009; 54: 477-486.
6 Yusuf S. et al. Comparison of fondaparinux and enoxaparin in acute coronary syndromes. N Engl J Med 2006; 354: 1464-1476.
7 Wallentin L. et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2009; 361: 1045-1057.
8 Held C. et al. Ticagrelor Versus Clopidogrel in Patients With Acute Coronary Syndromes Undergoing Coronary Artery Bypass Surgery Results From the PLATO (Platelet Inhibition and Patient Outcomes) Trial. J Am Coll Cardiol 2011; 57: 672-684.
9 Steg PG. et al. Ticagrelor versus clopidogrel in patients with ST-elevation acute coronary syndromes intended for reperfusion with primary percutaneous coronary intervention: A Platelet Inhibition and Patient Outcomes (PLATO) trial subgroup analysis. Circulation 2010; 122: 2131-2141.
10 Storey RF. et al. Inhibitory effects of ticagrelor compared with clopidogrel on platelet function in patients with acute coronary syndromes: the PLATO (PLATelet inhibition and patient Outcomes) PLATELET substudy. J Am Coll Cardiol 2010; 56: 1456-1462.
11 James S. et al. Ticagrelor versus clopidogrel in acute coronary syndromes in relation to renal function: results from the Platelet Inhibition and Patient Outcomes (PLATO) trial. Circulation 2010; 122: 1056-1067.
12 James S. et al. Ticagrelor vs. clopidogrel in patients with acute coronary syndromes and diabetes: a sub-study from the PLATelet inhibition and patient Outcomes (PLATO) trial. Eur Heart J 2010; 31: 3006-3016.
13 Wallentin L. et al. Effect of CYP2C19 and ABCB1 single nucleotide polymorphisms on outcomes of treatment with ticagrelor versus clopidogrel for acute coronary syndromes: a genetic substudy of the PLATO trial. Lancet 2010; 376: 1320-1328.
14 Cannon CP. et al. Comparison of ticagrelor with clopidogrel in patients with a planned invasive strategy for acute coronary syndromes (PLATO): a randomised double-blind study. Lancet 2010; 375: 283-293.
15 Serebruany VL. Viewpoint: Paradoxical excess mortality in the PLATO trial should be independently verified. Thromb Haemost 2011; 105: 752-759.
16 James S. et al. Comparison of ticagrelor, the first reversible oral P2Y(12) receptor antagonist, with clopidogrel in patients with acute coronary syndromes: Rationale, design, and baseline characteristics of the PLATelet inhibition and patient Outcomes (PLATO) trial. Am Heart J 2009; 157: 599-605.
17 Wiviott SD. et al. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2007; 357: 2001-2015.
18 Yusuf S. et al. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med 2001; 345: 494-502.
19 Yusuf S. et al. Effects of fondaparinux on mortality and reinfarction in patients with acute ST-segment elevation myocardial infarction: the OASIS-6 randomized trial. J Am Med Assoc 2006; 295: 1519-1530.
20 Stone GW. et al. Bivalirudin for patients with acute coronary syndromes. N Engl J Med 2006; 355: 2203-2216.